CA9 and prostate carcinoma: For example, 111In-labelled DOTA–girentuximab-IRDye800CW, a carbonic anhydrase IX-targeting antibody previously used in clear cell renal cell carcinoma19, and the monoclonal antibody D2B32 named 111In-labelled prostate-specific membrane antigen-IRDye800CW, which has been used in prostate carcinoma, have both seen promising results32.